ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1974

Diagnosis-Specific Combination of Cystatin C- and Creatinine-Based eGFR

Session Information

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology


  • Bokenkamp, Arend, Amsterdam UMC Locatie VUmc, Amsterdam, Noord-Holland, Netherlands
  • Oostdam, Tobias, Amsterdam UMC Locatie VUmc, Amsterdam, Noord-Holland, Netherlands
  • Björk, Jonas, Lunds Universitet, Lund, Sweden
  • Nyman, Ulf, Skanes universitetssjukhus Malmo, Malmo, Skåne, Sweden
  • Goffin, Karolien, Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Flanders, Belgium
  • Åsling Monemi, Kajsa, Karolinska Universitetssjukhuset, Stockholm, Sweden
  • Hansson, Magnus Daniel, Karolinska Universitetssjukhuset, Stockholm, Sweden
  • Berg, Ulla B., Karolinska Universitetssjukhuset, Stockholm, Sweden
  • Littmann, Karin, Karolinska Universitetssjukhuset, Stockholm, Sweden
  • Grubb, Anders O., Lunds Universitet, Lund, Sweden
  • Pottel, Hans, Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Flanders, Belgium
  • Den bakker, Emil, Amsterdam UMC Locatie VUmc, Amsterdam, Noord-Holland, Netherlands

The arithmetic mean of a creatinine- and a cystatin C-based GFR estimation (eGFR) has higher accuracy than either of the two. Smaller studies indicate that the relative contribution of the creatinine- and the cystatin C-based equation should be adapted based on underlying diagnosis.


Retrospective analysis of 1712 plasma clearance GFR measurements from four pediatric nephrology centers. eGFR was calculated using the height-based Full Age Spectrum equation using creatinine (FAS-creat) and the FAS-cys equation for cystatin C. α describes the contribution of FAS-creat, (1-α) the contribution of FAS-cys. 2/3 of the cohort (mean age 11.8 years, mGFR 93.8 ml/min/1.73m2) was used to determine the α-values yielding the highest P30 accuracy globally (FASα) and in diagnosis subgroups. These α-values were validated in the remaining 1/3 of the cohort assessing accuracy, bias and precision.


Globally, the optimal α-value was 0.3 [95% CI 0.2 – 0.4, Figure]. Lower α-values were determined for spina bifida (0), glomerulonephritis (0.2), and liver disease (0.25), while CAKUT, kidney transplantation and tubulointerstitial disease had α-values between 0.35 and 0.55.
Accuracy of FAS0.3 in the validation cohort was 90.2%, which was significantly higher than accuracy of the arithmetic mean (87.4%, p<0.05). Using the diagnosis-specific α-values rather than FAS0.3 improved bias (+2.5 vs +1.3 ml/min/1.73m2, p < 0.01) and precision (14.1 vs 13.8 ml/min/1.73m2, p < 0.05), while accuracy was unchanged. Only in children with spina bifida, a clinically relevant improvement was observed when using the diagnosis-specific α-value.


For calculation of the weighted mean, a fixed mix of 30% FAS-creat and 70% FAS-cys is optimal and yields very high accuracy overall. A disease-specific adaption (i.e. 100% cystatin C eGFR) is clinically relevant only for patients with spina bifida.